These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 25483463

  • 21. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A, Gómez-Lim MA, Weiss-Steider B, Hernández-Montes J, Huerta-Yepez S, Rangel-Santiago JF, Santiago-Osorio E, Mora García Mde L.
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [Abstract] [Full Text] [Related]

  • 22. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N.
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [Abstract] [Full Text] [Related]

  • 23. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.
    Thönes N, Herreiner A, Schädlich L, Piuko K, Müller M.
    J Virol; 2008 Jun; 82(11):5472-85. PubMed ID: 18385253
    [Abstract] [Full Text] [Related]

  • 24. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A, Bolhassani A, Javadi G, Noormohammadi Z.
    Sci Rep; 2019 Oct 23; 9(1):15225. PubMed ID: 31645650
    [Abstract] [Full Text] [Related]

  • 25. The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response.
    Bissa M, Zanotto C, Pacchioni S, Volonté L, Venuti A, Lembo D, De Giuli Morghen C, Radaelli A.
    Antiviral Res; 2015 Apr 23; 116():67-75. PubMed ID: 25660110
    [Abstract] [Full Text] [Related]

  • 26. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
    Xu D, Wang D, Yang X, Cao M, Yu J, Wang Y.
    Antiviral Res; 2014 Feb 23; 102():61-9. PubMed ID: 24333518
    [Abstract] [Full Text] [Related]

  • 27. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C, Dey B, Wahiduzzaman M, Singh N.
    Vaccine; 2012 Aug 03; 30(36):5417-24. PubMed ID: 22717329
    [Abstract] [Full Text] [Related]

  • 28. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.
    Murata Y, Lightfoote PM, Rose RC, Walsh EE.
    Virol J; 2009 Jun 18; 6():81. PubMed ID: 19538743
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.
    Hum Vaccin Immunother; 2014 Jun 18; 10(10):2965-74. PubMed ID: 25483632
    [Abstract] [Full Text] [Related]

  • 30. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X, Wang D, Liang F, Fu L, Guo C.
    Hum Vaccin Immunother; 2014 Jun 18; 10(12):3491-8. PubMed ID: 25483698
    [Abstract] [Full Text] [Related]

  • 31. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
    Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, Kleinschmidt JA.
    Vaccine; 2006 Apr 05; 24(15):2952-65. PubMed ID: 16414157
    [Abstract] [Full Text] [Related]

  • 32. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
    Motavalli Khiavi F, Arashkia A, Golkar M, Nasimi M, Roohvand F, Azadmanesh K.
    J Immunol Res; 2018 Apr 05; 2018():9464186. PubMed ID: 29854852
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Production of human papillomavirus type 16 virus-like particles in transgenic plants.
    Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M.
    J Virol; 2003 Sep 05; 77(17):9211-20. PubMed ID: 12915537
    [Abstract] [Full Text] [Related]

  • 35. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [Abstract] [Full Text] [Related]

  • 36. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants.
    Liu HL, Li WS, Lei T, Zheng J, Zhang Z, Yan XF, Wang ZZ, Wang YL, Si LS.
    Acta Biochim Biophys Sin (Shanghai); 2005 Mar 16; 37(3):153-8. PubMed ID: 15756416
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB.
    Cancer Res; 2006 Dec 01; 66(23):11120-4. PubMed ID: 17145854
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.